Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor

Summary

Cysteines play a key part in von Willebrand factor (VWF) dimerisation and polymerisation, and their loss may severely affect VWF structure and function. We report on three patients with type 3 von Willebrand disease carrying the new c.1751G>T missense mutation that induces the substitution of cysteine 584 by phenylalanine (C584F), and the deletion of seven nucleotides in exon 7 (c.729_735del), producing a premature stop codon at position 454 (E244Lfs*211). VWF was almost undetectable in the patients’ plasma and platelets, while a single, poorly represented, oligomer emerged on plasma VWF multimer analysis. No post-DDAVP increase in VWF and factor VIII was observed. Expressing human recombinant C584F-VWF in HEK293T cells showed that C584F-VWF was synthesised and multimerised but not secreted – apart from the first oligomer, which was slightly represented in the conditioned medium, with a pattern similar to the patients’ plasma VWF. The in vitro expression of the E244Lfs*211–VWF revealed a defective synthesis of the mutated VWF, with a behavior typical of loss of function mutations. Cellular trafficking, investigated in HEK293 cells, indicated a normal C584F-VWF content in the endoplasmic reticulum and Golgi apparatus, confirming the synthesis and multimerisation of C584F-VWF. No pseudo-Weibel Palade bodies were demonstrable, however, suggesting that C584F mutation impairs the storage of C584F-VWF. These findings point to cysteine 584 having a role in the release of VWF and its targeting to pseudo-Weibel Palade bodies in vitro, as well as in its storage and release by endothelial cells in vivo.

Keywords

von Willebrand factor - von Willebrand disease - VWF propeptide - VWF gene mutations - VWF multimerisation

• References

• 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
• 2 Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257-279.
• 3 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 04: 2103-2114.
• 4 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-1909.
• 5 Nachman RL, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 1977; 60: 914-921.
• 6 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 06: 217-246.
• 7 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localisation. J Biol Chem 1984; 99: 2123-2130.
• 8 Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM. et al. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69: 27-32.
• 9 Wagner DD, Fay PJ, Sporn LA. et al. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Scie USA 1987; 84: 1955-1959.
• 10 Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol 1964; 23: 101-112.
• 11 Sadler JE. von Willebrand factor assembly and secretion. Thromb Haemost 2009; 07: 24-27.
• 12 Zenner 1 HL, Collinson LM, Michaux G. et al. High-pressure freezing provides insights into Weibel-Palade body biogenesis. J Cell Sci 2007; 120: 2117-2125.
• 13 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localisation. J Cell Biol 1984; 99: 2123-2130.
• 14 De Ceunynck 1 K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Wille-brand factor strings puzzle. Blood 2013; 121: 270-277.
• 15 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 16 Casonato A, De Marco L, Mazzuccato M. et al. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Wille-brand factor platelet interaction and the presence of all von Willebrand factor multimers in plasma. Blood 1989; 74: 2028-2033.
• 17 Casonato A, Sartori MT, Pontara E. et al. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand’s disease with low platelet von Willebrand factor content. Blood Coagul Fibrinolysis 1992; 03: 149-153.
• 18 Girolami A, Molaro G, Lazzarin M. et al. A new congenital haemorrhagic condition due to the presence of abnormal factor X (factor X Friuli): study of a large kindred. Br J Haematol 1970; 19: 179-192.
• 19 Casonato A, Pontara E, Bertomoro A. et al. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. J Lab Clin Med 1997; 129: 251-259.
• 20 Mancuso DJ, Tuley EA, Westfield LA. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
• 21 Zampese E, Fasolato C, Kipanyula MJ. et al. Presenilin 2 modulates endoplasmic reticulum (ER) - mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci USA 2011; 108: 2777-2782.
• 22 Manders EM, Verbeek FJ, Aten JA. Measurement of co-localisation of objects in dual-color confocal images. J. Microsc 1993; 169: 375-382.
• 23 Rasband WS. Image J. U. S. National Institutes of Health, Bethesda, Maryland, USA,. http://imagej.nih.gov/ij 1997-2014.
• 24 Michaux G, Hewlett LJ, Messenger SL. et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Wille-brand factor. Blood 2003; 102: 2452-2458.
• 25 Katsumi A, Tuley EA, Bodo I. et al. Localisation of disulfide bonds in the cysteine knot domain of human von Willebrand factor. J Biol Chem 2000; 275: 25585-25594.
• 26 Rehemtulla A, Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide processing enzymes. Blood 1992; 79: 2349-2355.
• 27 Wise RJ, Pittman DD, Handin RI. et al. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 1988; 52: 229-236.
• 28 Purvis AR, Sadler EJ. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerisation. J Biol Chem 2004; 26: 49982-49988.
• 29 Verwey CL, Hart M, Pannekock H. Expression of von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J 1987; 06: 2885-2890.
• 30 Schneppenheim R, Budde U, Krey S. et al. Defective dimerisation of von Wille-brand factor subunits due to a Cys-Arg mutation in type 2D von Willebrand disease. Proc Natl Acad Sci USA 1996; 93: 3581-3586.
• 31 Burgess J, Jauregui M, Tan J. et al. AP-1 and clathrin are essential for secretory granule biogenesis in Drosophila. Mol. Biol. Cell 2011; 22: 2094-2105.
• 32 Lui-Roberts WW, Collinson LM, Hewlett LJ. et al. An AP-1/clathrin coat plays a novel and essential role in forming the Weibel-Palade bodies of endothelial cells. J. Cell Biol 2005; 170: 627-636.
• 33 Nightingale T, Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost 2013; 11: 192-201.
• 34 Lanke E, Kristoffersson AC, Philips M. et al. Characterisation of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease. Thromb Haemost 2008; 100: 211-216.